A. McInnes

Contribution of Stroke to the Cochrane Stroke Group Trials Register.

P. Sandercock, B. Thomas, A. McInnes, 2003, Stroke.

Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells

D. Rennick, A. McInnes, 1988, The Journal of experimental medicine.

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.

G. Pentheroudakis, J. Paul, T. Evans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a phase 1 and PK study of capecitabine (XEL) in combination with epirubicin (E) and cisplatin (C) [ECC] in patients with advanced oesophagogastric (OG) adenocarcinoma

J. Paul, T. Evans, A. Mcdonald, 2001 .

A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.

A. Harris, H. Mackay, J. Paul, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Use of C-Reactive Protein for Prognostic Stratification in Ischemic Stroke: Has the Time Come for Including It in the Patient Risk Profile?

P. Sandercock, C. Anderson, P. Langhorne, 2012 .

Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease

J. Brotchie, A. Crossman, M. Silverdale, 2001, Experimental Neurology.

The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989.

P. Sandercock, B. Pentland, C. Warlow, 1992, Journal of neurology, neurosurgery, and psychiatry.

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis

A. Heald, I. Kasujee, A. McInnes, 2022, Dermatology and Therapy.

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

D. Jodrell, C. Twelves, J. Cassidy, 1998, British Journal of Cancer.